Silence Therapeutics PLC Form 4 insider transactions

Director Richard Ian Griffiths reports acquiring additional American Depositary Shares (ADS) of Silence Therapeutics plc, increasing his beneficial ownership.

Richard Ian Griffiths, a director of Silence Therapeutics plc, reported the disposal of 100,000 American Depositary Shares on March 31, 2025.

Director Richard Ian Griffiths reports acquiring Silence Therapeutics shares through Cream Capital Limited in multiple transactions.

Director Richard Ian Griffiths reports acquisition of Silence Therapeutics plc shares through Cream Capital Limited.

Director Richard Ian Griffiths reports multiple transactions involving the purchase of Silence Therapeutics plc American Depositary Shares (ADS) and ordinary shares.

Director James Ede-Golightly acquired share options in Silence Therapeutics plc on January 2, 2025.

Director Michael H. Davidson acquires share options in Silence Therapeutics plc.

Director Iain Ross acquired 90,000 share options in Silence Therapeutics plc on January 2, 2025.

Director David Lemus acquired share options in Silence Therapeutics plc on January 2, 2025, according to a Form 4 filing.

Steven J. Romano, EVP and Chief R&D Officer of Silence Therapeutics plc, was granted options to purchase 285,000 ordinary shares.

Rhonda Lynette Hellums, CFO of Silence Therapeutics plc, was granted 375,000 employee share options on January 2, 2025.

Craig A. Tooman, CEO of Silence Therapeutics plc, was granted options to purchase 900,000 ordinary shares on January 2, 2025.